dm+d

407033009

Articles

Safety in Lactation: Antidepressants

21 October 2020Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Monamine-oxidase inhibitors (MAOIs) Due to the…

Safety in Lactation: Drugs for urinary frequency, enuresis, and incontinence

25 September 2020This group of drugs have varied mechanisms of action in treating urinary control conditions. Indications are broadly similar for all drugs, although there are small…

What is serotonin syndrome and which medicines cause it?

22 May 2020This Medicines Q&A outlines the causes and symptoms of serotonin syndrome and provides examples of medicines with the potential to cause serotonin syndrome.  

Drugs for urinary disorders – are any lactose-free?

5 February 2020This Medicine Q&A gives details of available urinary frequency, enuresis, incontinence and urinary retention preparations that do not contain lactose. There is a lactose-free preparation…

What evidence is available for the use of antidepressants for the management of menopausal hot flushes?

26 November 2019This is one of two UKMi Medicines Q&As addressing the management of menopausal hot flushes (vasomotor symptoms) with non-hormonal drug therapy.
Search Articles

Medicine Compliance Aid Stability

CymbaltaEli Lilly and Co Ltd

Eli Lilly and Co Ltd
Cymbalta
Capsules 30mg, 60mg
A3 · Amber 3No stability data is available. There are theoretical concerns with use in CAs, which may be mitigated by risk minimisation.
Protect from moisture
Protect from moisture.
26 October 2015

YentreveEli Lilly and Co Ltd

Eli Lilly and Co Ltd
Yentreve
Capsules 20mg, 40mg
R2 · Red 2Drug is not suitable for CAs due to theoretical reasons that cannot be mitigated.
Unsuitable
Protect from moisture. Store in original pack
21 September 2015

genericDr Reddy's Laboratories (UK) Ltd

Dr Reddy's Laboratories (UK) Ltd
generic
Capsules 30mg, 60mg
G2 · Green 2No stability data is available, but manufacturer suggests it is suitable for use in CAs.
Protect from light
Protect from moisture
Protect from light. Protect from moisture. Max 28 days in MCA.
26 October 2015

Lactation Safety Information

For depression

For depression
TCA: imipramine/nortriptyline SSRI: paroxetine/sertraline
Limited published evidence of safety
Small amounts found in breast milk that are likely to be degraded in infant’s GI tract, although relatively long half life increases risk of accumulation in breastfed infants
Monitor infant for drowsiness, poor feeding, irritability/behavioural effects
17 September 2018

For urinary incontinence

For urinary incontinence
Limited published evidence of safety
Small amounts in breast milk that are likely to be degraded in infant’s GI tract, although long half life increases risk of accumulation in breast fed infants
Monitor infant for drowsiness, poor feeding, irritability/ behavioural effects
17 September 2018